These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 27738308)

  • 1. Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma.
    Zhou N; Liu C; Hou H; Zhang C; Liu D; Wang G; Liu K; Zhu J; Lv H; Li T; Zhang X
    Oncotarget; 2016 Nov; 7(44):72373-72379. PubMed ID: 27738308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
    Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
    BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.
    Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Wu J; Zhuang W; Fei J; Wen Y; Jiang X
    Clin Colorectal Cancer; 2018 Sep; 17(3):e443-e449. PubMed ID: 29576426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remarkable response with pembrolizumab plus albumin-bound paclitaxel in 2 cases of HER2-positive metastatic breast cancer who have failed to multi-anti-HER2 targeted therapy.
    Li B; Tao W; Shao-Hua Z; Ze-Rui Q; Fu-Quan J; Fan L; Ze-Fei J
    Cancer Biol Ther; 2018 Apr; 19(4):292-295. PubMed ID: 29333945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.
    Hu X; Zhang J; Xu B; Jiang Z; Ragaz J; Tong Z; Zhang Q; Wang X; Feng J; Pang D; Fan M; Li J; Wang B; Wang Z; Zhang Q; Sun S; Liao C
    Int J Cancer; 2014 Oct; 135(8):1961-9. PubMed ID: 24604288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
    Clavarezza M; Turazza M; Aitini E; Saracchini S; Garrone O; Durando A; De Placido S; Bisagni G; Levaggi A; Bighin C; Restuccia E; Scalamogna R; Galli A; Del Mastro L
    Breast; 2013 Aug; 22(4):470-5. PubMed ID: 23642526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term complete response in a patient with liver metastases from breast cancer treated with metronomic chemotherapy.
    Cecconetto L; Casadei Gardini A; Tenti E; Maltoni R; Bravaccini S; Oboldi D; Zoli W; Serra P; Donati C; Sarti S; Amadori D; Rocca A
    Tumori; 2014; 100(3):e79-82. PubMed ID: 25076256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
    Gao Z; Shi M; Wang Y; Chen J; Ou Y
    Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metaplastic breast cancer with a unique presentation and complete response to chemotherapy: a case report.
    Nahhat F; Doyya M; Zabad K; Ksiri H
    BMC Womens Health; 2024 May; 24(1):285. PubMed ID: 38734591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer.
    von der Lippe Gythfeldt H; Lien T; Tekpli X; Silwal-Pandit L; Borgen E; Garred Ø; Skjerven H; Schlichting E; Lundgren S; Wist E; Naume B; Kristensen V; Børresen-Dale AL; Lingjaerde OC; Engebraaten O
    Int J Cancer; 2020 Nov; 147(9):2515-2525. PubMed ID: 32488909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature.
    Ding L; Li QJ; You KY; Jiang ZM; Yao HR
    Medicine (Baltimore); 2016 May; 95(20):e3598. PubMed ID: 27196461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Profiling of the Metaplastic Spindle Cell Carcinoma of the Breast Reveals Potentially Targetable Biomarkers.
    Vranic S; Stafford P; Palazzo J; Skenderi F; Swensen J; Xiu J; Spetzler D; Gatalica Z
    Clin Breast Cancer; 2020 Aug; 20(4):326-331.e1. PubMed ID: 32197944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy.
    Liu Z; Ou W; Li N; Wang SY
    Thorac Cancer; 2018 Oct; 9(10):1285-1290. PubMed ID: 30126078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.
    Ferrero JM; Hardy-Bessard AC; Capitain O; Lortholary A; Salles B; Follana P; Herve R; Deblock M; Dauba J; Atlassi M; Largillier R
    Cancer; 2016 Oct; 122(20):3119-3126. PubMed ID: 27412268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.
    Tanaka S; Iwamoto M; Kimura K; Matsunami N; Morishima H; Yoshidome K; Nomura T; Morimoto T; Yamamoto D; Tsubota Y; Kobayashi T; Uchiyama K
    Clin Breast Cancer; 2015 Jun; 15(3):191-6. PubMed ID: 25579459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer.
    A L-Tweigeri T; AlSayed A; Alawadi S; Ibrahim M; Ashour W; Jaafar H; Abulkhair O; A L-Abdulkarim H; Khalid H; Ajarim D;
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):147-53. PubMed ID: 26563257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine.
    Curigliano G; Bagnardi V; Bertolini F; Alcalay M; Locatelli MA; Fumagalli L; Rabascio C; Calleri A; Adamoli L; Criscitiello C; Viale G; Goldhirsch A
    Breast; 2015 Jun; 24(3):263-71. PubMed ID: 25772326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.
    Masuda N; Higaki K; Takano T; Matsunami N; Morimoto T; Ohtani S; Mizutani M; Miyamoto T; Kuroi K; Ohno S; Morita S; Toi M
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):229-38. PubMed ID: 24871032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A Case of Triple Negative Spindle Cell Carcinoma of the Breast and Improved Quality of Life Following Irinotecan Chemotherapy].
    Ogura N; Tsunekawa S; Okabe A; Sugimoto T; Nishiyama K; Oshima Y; Hosoda Y; Kiyochi H; Komoto I; Taki Y; Katsushima U; Yanagihara K; Kawai J
    Gan To Kagaku Ryoho; 2017 Dec; 44(13):2097-2099. PubMed ID: 29361625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.